Estradiol Transdermal Patch and Atazanavir: Interaction Details
- Atazanavir
- Reyataz
- Estradiol Transdermal Patch
- ClimaraMenostarMinivelle +13 more
Medically reviewed by Dr. Brian Staiger, PharmD, BCPS
Also reviewed by the HelloPharmacist Editorial Team Updated AI-assisted Details about this page
- Dr. Brian Staiger, PharmD, BCPS, is a clinical pharmacist and pharmacotherapy specialist.
- AI-assisted, written
- AI is used only to summarize verified clinical information, never the open internet.
- Editorial policy
- How we build our interaction pages →
- Our AI policy →
A close look at the Estradiol Transdermal Patch and Atazanavir interaction:
Estradiol Transdermal Patch
- Climara
- Menostar
- Minivelle
- Vivelle-Dot
- Alora
- Esclim
- Estraderm
- FemPatch
- Vivelle
- Yuvafem
- Imvexxy
- Estrace
- Depo-estradiol
- Delestrogen
- Dotti
- Lyllana
What Happens When You Take Estradiol Transdermal Patch With Atazanavir
What can happen when they are taken together (rated Moderate)
An increase in exposure to the combination contraceptive
Interaction Deep Dive
A note from Dr. Brian Staiger If you’re a patient, this deep dive may be too technical, or bore you (or both). Read the plain-language explanation →
Oral contraceptives should be prescribed with caution in patients who are taking atazanavir. The recommended option is a combination oral contraceptive containing an appropriate ethinyl estradiol dose: at least 35 mcg when atazanavir is given together with ritonavir, and no more than 30 mcg when atazanavir is given alone.
Because no studies have been done, a different contraceptive method is advised if the patient uses other hormonal products (eg, patch, vaginal ring, injection), oral contraceptives with a progestin other than norethindrone or norgestimate, or oral contraceptives with less than 25 mcg of ethinyl estradiol.1 In a study of healthy HIV-negative women (n=20), giving atazanavir/ritonavir with an oral contraceptive made up of ethinyl estradiol and norgestimate raised norgestimate exposure and lowered ethinyl estradiol exposure.
The drop in ethinyl estradiol levels was not expected to reduce contraceptive . The findings suggest that an oral contraceptive providing at least 30 mcg of ethinyl estradiol would be enough to keep ethinyl estradiol exposure adequate.2
The Estradiol Transdermal Patch and Atazanavir Interaction, Explained
Atazanavir is an HIV medicine, and the estradiol patch is a hormone patch. The record says taking atazanavir with hormone products may raise your exposure to the hormones in them, and the exact reason isn't known. It could mean more hormone side effects, such as breast tenderness, nausea, or headaches.
The best evidence comes from birth control pills, not from the estradiol patch itself. Patches have not been studied with atazanavir. Please keep using both as prescribed. Let your pharmacist or doctor know you take both. They can tailor your hormone dose, check how you are feeling, and choose the best option for you.
Interaction: Atazanavir (with or without ritonavir) may increase exposure to the hormonal contraceptive. The mechanism is unknown. Onset is unspecified. Evidence is rated probable, severity moderate.
- In healthy HIV-negative women (n=20), atazanavir/ritonavir with ethinyl estradiol/norgestimate increased norgestimate exposure and decreased ethinyl estradiol exposure. Other data show both reductions and elevations in ethinyl estradiol.
- No studies exist for transdermal or other non-oral hormonal products. This estradiol patch is a non-oral product and is not covered by the oral data, so extrapolation is limited.
- Management: Labeling advises an alternative contraceptive method when atazanavir is used with a patch, ring, or injection. Oral products need ethinyl estradiol ≥35 mcg with ritonavir, or ≤30 mcg without it. Individualize therapy and monitor for estrogenic or progestogenic adverse effects.
See the 2 references behind this explanation ↓
From the HelloPharmacist Pharmacy Team
AI-assisted: written with AI from this pair’s record in our interaction database, and reviewed by the HelloPharmacist pharmacy team. Written .
How we build these pages · How we use AI · Our editorial policy
Why Estradiol Transdermal Patch and Atazanavir Interact
The likely mechanism
Unknown
“Unknown” here means the studies and labels behind this record do not say how the interaction happens. It does not mean the interaction is unlikely.
How to Manage the Estradiol Transdermal Patch and Atazanavir Interaction
Your care team can manage this by individualizing your hormone therapy and checking in with you more closely.
- Keep taking both medicines as prescribed. Do not stop or change either one on your own.
- If your estradiol patch is used for contraception, ask your prescriber about an alternative method, since patches have not been studied with atazanavir.
- Tell your pharmacist or prescriber if you also take ritonavir or any other hormonal product.
- Report new side effects such as breast tenderness, nausea, headache, or unexpected bleeding.
Management is individual — confirm any change with your pharmacist or prescriber.
Questions for Your Pharmacist
- Does my dose of Estradiol Transdermal Patch or Atazanavir need adjusting while I take them together?
- What symptoms should prompt me to call you or my prescriber right away?
- Does the timing of my doses matter for this combination?
- Is there anything you'd monitor while I'm on both?
Literature Reports
2 reports from the published literature. Each one is headed by the title of the published study it comes from.
What these reports are. Short summaries of published evidence on this combination: clinical studies, case reports and, at times, the FDA prescribing information for one of the drugs. They support this interaction, but it does not rest on them alone. It can also rest on prescribing information not summarized here, or on what is expected from how these two drugs, and others in their drug classes, are known to work.
-
Report 1 · Study title
Prescribing information: REYATAZ oral capsules, oral powder, atazanavir oral capsules, oral powder
Use of atazanavir (with or without ritonavir) together with a combination ethinyl estradiol/norgestimate or norethindrone oral contraceptive has led to substantial increases in progesterone exposure. The long-term consequences of higher progestational agent are unknown and could include a greater risk of insulin resistance, dyslipidemia, and acne.
When atazanavir 300 mg plus ritonavir 100 mg once daily was given with an ethinyl estradiol/norgestimate oral contraceptive, ethinyl estradiol exposure decreased and norgestimate exposure increased. When atazanavir 400 mg once daily was coadministered with an ethinyl estradiol/norethindrone contraceptive, exposure to both ethinyl estradiol and norethindrone increased. No studies have evaluated atazanavir (with or without ritonavir) given with other hormonal contraceptives (eg, patch, vaginal ring, or injection), with oral contraceptives containing progestins other than norethindrone or norgestimate, or with oral contraceptives containing less than 25 mcg of ethinyl estradiol.1
-
Report 2 · Study title
The effect of atazanavir/ritonavir on the pharmacokinetics of an oral contraceptive containing ethinyl estradiol and norgestimate in healthy women
In a study of healthy HIV-negative women (n=20; mean age 28 years), giving atazanavir/ritonavir with an oral contraceptive containing ethinyl estradiol (EE) and norgestimate (NGM) increased norgestimate exposure and decreased ethinyl estradiol exposure; however, the lower ethinyl estradiol levels were not expected to reduce contraceptive . In this open-label, three-period study, participants took a full 28-day cycle of Ortho Tri-CyClen(R) (EE 0.035 mg plus NGM 0.18/0.215/0.25 mg) during the lead-in period.
In period 1, they then took a second cycle of daily Ortho Tri-CyClen(R) (treatment A). Participants with satisfactory safety assessments started a third cycle on day 29 with Ortho Tri-Cyclen LO(R) (EE 0.025 mg plus NGM 0.18/0.215/0.25 mg) coadministered with atazanavir 300 mg/ritonavir 100 mg once daily for 14 days (treatment B).
Dose normalization was carried out to account for the different EE doses in the 2 treatments and to estimate the size of the reduction in EE exposure. With atazanavir/ritonavir plus dose-normalized EE/NGM, geometric mean EE reductions were 16%, 19%, and 37% for , , and Cmin, respectively.
NGM Cmax, AUC, and Cmin increased by 68%, 85%, and 102%, respectively. The results indicate that an oral contraceptive containing at least 30 mcg of EE would be adequate to maintain sufficient EE exposure. Because the contraceptive efficacy of Ortho Tri-Cyclen(R) depends mainly on the progestin, efficacy was not expected to be compromised.2
Estradiol Transdermal Patch and Atazanavir: Common Questions
How serious is the Estradiol Transdermal Patch and Atazanavir interaction?
It is rated moderate. Can be significant — usually manageable with monitoring.
How is the Estradiol Transdermal Patch and Atazanavir interaction managed?
Your care team can manage this by individualizing your hormone therapy and checking in with you more closely. Keep taking both medicines as prescribed. Do not stop or change either one on your own. If your estradiol patch is used for contraception, ask your prescriber about an alternative method, since patches have not been studied with atazanavir. Tell your pharmacist or prescriber if you also ta… Management is individual — always follow your own care team's guidance.
Is there an alternative to taking Estradiol Transdermal Patch with Atazanavir?
If your estradiol patch is used for contraception, ask your prescriber about an alternative method, since patches have not been studied with atazanavir.
Only your prescriber can decide whether a change fits you, so talk with them before changing either medicine.
How quickly could this interaction happen?
The documented onset is "unspecified". The timing of this interaction is not well characterized.
How strong is the evidence for this interaction?
The evidence is graded "probable". Good supporting evidence, though not definitively proven.
Ask About the Estradiol Transdermal Patch and Atazanavir Interaction
Ask in your own words about taking Estradiol Transdermal Patch and Atazanavir together. The answer comes from this page’s interaction record and both drugs’ own information.
This box answers questions about this one combination only. For anything else about either drug, open its drug information page or ask a pharmacist.
AI answers from this page’s record and both drugs’ information, never the open internet. AI can make mistakes, so always check with your doctor or pharmacist.
References (2)
- Product Information: REYATAZ(R) oral capsules, oral powder, atazanavir oral capsules, oral powder. Bristol-Myers Squibb Company (per FDA), Princeton, NJ, 2023. DailyMed
- Zhang J, Chung E, Yones C, et al: The effect of atazanavir/ritonavir on the pharmacokinetics of an oral contraceptive containing ethinyl estradiol and norgestimate in healthy women. Antivir Ther 2011; 16(2):157-164. PubMed
Other Serious Interactions of Estradiol Transdermal Patch and Atazanavir
Also serious with Atazanavir
- ColchicineContraindicated
- SimvastatinContraindicated
- AlfuzosinContraindicated
- Dihydroergotamine InjectionContraindicated
Also serious with Estradiol Transdermal Patch
These Medications Also Interact With Supplements
Prescription drugs aren't the whole picture — herbal and dietary supplements can interact with them too. From the evidence-graded Natural Medicines database:
With Atazanavir
- GrapefruitMajor
- St. John's WortMajor
- Activated CharcoalMajor
- Vitamin EModerate
- GingerModerate
- TurmericModerate
- Green TeaModerate
- Black PepperModerate
- + 149 more
Check everything you take with our drug–supplement interaction checker.
Still Have Questions About This Combination?
Every question gets a real answer from a licensed pharmacist — free, as soon as they can.
About This Library
Built in-house, documented one interaction at a time. Our interaction database is not a complete list of every known interaction: a combination that isn't listed here hasn't been documented by us yet, which never means it's safe. Checking everything you take at once? Ask your pharmacist to review your full medication list. How we build and review it →
What Each Rating Means
Severity Levels
- Contraindicated These should generally not be used together.
- Major Potentially serious — often needs a change or close monitoring.
- Moderate Can be significant — usually manageable with monitoring. This interaction.
- Minor Usually limited clinical impact.
Evidence Grades
- EstablishedWell documented — supported by controlled studies or strong clinical data.
- ProbableGood supporting evidence, though not definitively proven. This interaction.
- SuspectedSome evidence suggests this interaction, but it is not well established.
- PossibleLimited or conflicting evidence; the interaction may occur.
- TheoreticalExpected from how the drugs work, or from studies of similar drugs; this exact pair has little direct study.
How Soon It Shows
- RapidEffects can appear quickly, often within about 24 hours of combining the drugs.
- DelayedEffects tend to build up gradually over days to weeks.
- UnspecifiedThe timing of this interaction is not well characterized. This interaction.
Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.